Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use

Katherine A. Lyseng-Williamson
Conflicts of interest: K.A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest. Funding: The preparation of this review was not supported by any external funding. Additional information about this Adis Drug Review may be found here. Abstract The triple-component fixed-dose combination of olmesartan medoxomil (OLM)/amlodipine (AML)/hydrochlorothiazide (HCT) is a rational choice for patients who require treatment with three or more antihypertensives. The three...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.